Thursday, November 16, 2017 1:22:00 PM
FY2017 and 1Q18 reports have been filed.
You had conveyed OMHE business plan in Feb 2017. Since then OMHE acquired new business, inducted scientists, established advanced Biotech R&D lab, conducting research to develop cannabinoid-based drug therapies. Latest update was provided on 11/14/2017: cannabinoid-based pain treatment medicine is ready to be marketed; talks are underway with large European companies. Target markets include North America, Europe, Australia and Asia.
I am satisfied with OMHE's progress!!
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM